San Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.

Aradigm Corp.’s inhaled antibiotic for a rare, incurable disorder affecting the lungs failed a late-stage study, sending the company’s shares down in premarket trading.